Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OCUSERT PILO-40 vs PROVOCHOLINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Direct-acting muscarinic agonist; mimics acetylcholine at muscarinic receptors in the eye, causing ciliary muscle contraction and pupillary sphincter contraction, leading to miosis and increased aqueous humor outflow.
Parasympathomimetic agent that acts as a direct cholinergic agonist at muscarinic receptors, increasing exocrine gland secretion.
Open-angle glaucoma,Ocular hypertension,Angle-closure glaucoma (emergency treatment),Induction of miosis during ophthalmic surgery,Off-label: Diagnostic miosis
FDA: Diagnosis of bronchial airway hyperreactivity in subjects without clinically apparent asthma.,Off-label: Treatment of xerostomia, glaucoma.
One OCUSERT Pilo-40 (2.5 mcg/hr pilocarpine) inserted into the conjunctival cul-de-sac every 7 days.
Subcutaneous: 2.5-5 mg; if no response, repeat with 5-10 mg; maximum single dose 10 mg.
Terminal elimination half-life is approximately 1-2 hours; clinical effect duration is extended due to the sustained-release delivery system.
Terminal elimination half-life is 1-2 hours in patients with normal renal function. However, due to rapid hydrolysis by plasma and tissue cholinesterases, the actual duration of effect is brief (minutes). Clinical context: half-life may be prolonged in patients with reduced cholinesterase activity or renal impairment.
Primarily metabolized by plasma esterases via hydrolysis, with minor hepatic metabolism (CYP450 not significantly involved).
Primarily metabolized by acetylcholinesterase.
Primarily renal (80-90% as unchanged drug and inactive metabolites); biliary/fecal excretion accounts for <5%.
Primarily renal excretion of unchanged drug and inactive metabolites. Approximately 80-90% of administered dose is excreted renally. No significant biliary or fecal elimination.
Binding to plasma proteins is negligible (<10%); primarily bound to tissue proteins in the eye.
Very low protein binding (<5%). Does not significantly bind to albumin or other plasma proteins.
0.3-0.6 L/kg in systemic circulation; local ocular distribution is extensive but systemic Vd is low.
Approximately 0.1-0.2 L/kg. Small Vd indicates limited extravascular distribution, consistent with a quaternary ammonium compound that does not readily cross cell membranes or the blood-brain barrier.
Systemic bioavailability is minimal (<1%) due to local ocular administration and first-pass hydrolysis; virtually 100% of the released dose is available locally in the eye.
Subcutaneous: approximately 90-100%. Oral: Very low (<2%) due to extensive presystemic metabolism by cholinesterases in the gastrointestinal tract and liver. Not administered orally. Inhalation: Variable, but effective locally; systemic absorption is minimal.
No specific adjustment required; pilocarpine is primarily metabolized in the eye and systemic absorption minimal. GFR not relevant.
No specific guidelines; use caution in severe renal impairment.
No specific adjustment required; pilocarpine undergoes minimal hepatic metabolism. Child-Pugh not applicable.
No specific guidelines; use caution in severe hepatic impairment.
Not established; safety and efficacy in pediatric patients not determined. Use only if clearly needed.
Safety and efficacy not established; use not recommended.
No specific dose adjustment; consider potential increased risk of systemic effects due to reduced tear production or conjunctival changes. Monitor for bradycardia, hypotension, or bronchospasm.
Use with caution due to potential for increased sensitivity and comorbidities; consider starting at lower end of dosing range.
No FDA black box warning.
Severe asthma or wheezing; administration to patients with asthma can cause fatal bronchospasm.
Risk of retinal detachment, especially in patients with pre-existing retinal disease or high myopia,May cause transient or permanent miosis leading to reduced vision in low light,Ciliary spasm, headache, and brow ache,Potential for systemic absorption causing bradycardia, hypotension, and bronchospasm,Caution in patients with asthma, bradycardia, or hypotension
Should be administered only by trained personnel; emergency resuscitative equipment must be immediately available; may cause bronchoconstriction, bradycardia, hypotension; use caution in patients with cardiovascular disease, epilepsy, hyperthyroidism, peptic ulcer, urinary obstruction.
Hypersensitivity to pilocarpine or any component,Patients with acute inflammatory disease of the eye (e.g., iritis, uveitis),Uncontrolled asthma or severe bradycardia (systemic effects)
Asthma, COPD, severe cardiac disease, recent myocardial infarction, hypotension, hypertension, hyperthyroidism, epilepsy, Parkinson's disease, peptic ulcer, gastrointestinal or urinary obstruction, pregnancy (Category C).
No significant food interactions known. Maintain adequate fluid intake. Avoid alcohol, which may increase risk of side effects like dizziness or blurred vision.
Avoid caffeine-containing foods and beverages (coffee, tea, chocolate, cola) for at least 6 hours prior to bronchial challenge testing as they can affect airway reactivity.
Pilocarpine is a pregnancy category C drug. Animal studies have shown embryotoxic effects. In the first trimester, there is a potential risk of malformations. In the second and third trimesters, use may cause fetal bradycardia and hypotension. The benefit must justify the potential risk.
Pregnancy Category C. Based on animal studies and limited human data, PROVOCHOLINE (methacholine) is not expected to increase the risk of major congenital malformations. However, bronchial provocation testing is generally avoided during pregnancy due to potential maternal hypoxia and fetal distress. First trimester: theoretical risk from maternal hypoxia; second and third trimesters: risk of preterm labor and fetal hypoxia if severe bronchospasm occurs.
Pilocarpine is excreted into breast milk. The M/P ratio is not established. Due to potential for systemic absorption in the infant, use while breastfeeding is not recommended. Monitor infant for cholinergic effects.
No human data on excretion in breast milk. Methacholine is rapidly hydrolyzed by plasma cholinesterases; systemic absorption after inhalation is minimal. M/P ratio is unknown. Caution is advised, but risk to nursing infant is likely low given rapid metabolism and low bioavailability.
Pregnancy may alter the pharmacokinetics of pilocarpine due to increased plasma volume and enhanced metabolic clearance. However, specific dose adjustment guidelines are not established. Titrate to the lowest effective dose to control intraocular pressure and monitor for systemic effects.
No specific dosing adjustments are recommended for methacholine challenge testing during pregnancy; however, the test is typically deferred due to potential risks. If conducted, start with lowest concentration (0.025 mg/m L) and titrate cautiously with close monitoring due to possible increased sensitivity of airway receptors and altered pharmacokinetics (increased plasma volume and decreased cholinesterase activity may prolong effects).
Ocusert Pilo-40 is a sustained-release ocular insert delivering pilocarpine 40 mcg/hr for 7 days. Instruct patient to insert into conjunctival cul-de-sac at bedtime to minimize initial blurring and brow ache. Monitor for signs of retinal detachment, especially in myopic patients. Contraindicated in acute iritis, shallow anterior chamber, and narrow-angle glaucoma (can worsen angle closure). Use with caution in patients with corneal abrasions or ulcers. Systemic absorption can cause bradycardia, hypotension, and increased GI motility.
Provocholine (methacholine chloride) is used for bronchial challenge testing to diagnose airway hyperreactivity in patients with suspected asthma but normal baseline spirometry. Administer with a nebulizer in increasing concentrations (0.025 to 25 mg/m L). Contraindicated in patients with FEV1 < 60% predicted, recent myocardial infarction, severe hypertension, or known hypersensitivity. Emergency resuscitation equipment must be available. Monitor for bronchospasm, oxygen desaturation, and treat with short-acting beta-agonists if needed.
Wash hands before handling the insert. Do not touch the eye with the insert.,Insert the oval-shaped Ocusert into the lower conjunctival sac at bedtime; it should not be felt after placement.,The insert works for 7 days; replace with a new one weekly. Remove at the end of the week and discard.,Do not wear contact lenses with Ocusert in place. Remove lenses before insertion and wait 15 minutes before reinserting after removal.,Expect temporary blurred vision and brow ache for the first few hours to days; these side effects often decrease with continued use.,If the insert falls out, rinse it with cool tap water and reinsert quickly. If lost or damaged, use a new one.,Report severe eye pain, vision changes, or redness immediately.,Avoid driving or operating machinery until you know how this medication affects your vision.,Keep out of reach of children; do not use after expiration date.
This test measures how sensitive your airways are to a substance that can cause narrowing.,You will inhale increasing doses of methacholine through a nebulizer while your breathing is tested.,Inform your doctor if you have asthma, recent heart attack, high blood pressure, or are pregnant.,Do not use caffeine or tobacco for at least 6 hours before the test.,Avoid using inhaler medications (e.g., albuterol) for 8-12 hours before the test as directed.,You may experience coughing, chest tightness, or shortness of breath during the test.,The test is stopped if your breathing drops significantly, and medication will be given to reverse effects.
No interactions on record
"The serum concentration of Bupropion can be increased when it is combined with Choline."
"The therapeutic efficacy of Acemetacin can be decreased when used in combination with Choline."
"The serum concentration of Choline can be increased when it is combined with Tipiracil."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OCUSERT PILO-40 vs PROVOCHOLINE, answered by our medical review team.
OCUSERT PILO-40 is a Ophthalmic Cholinergic Agonist that works by Direct-acting muscarinic agonist; mimics acetylcholine at muscarinic receptors in the eye, causing ciliary muscle contraction and pupillary sphincter contraction, leading to miosis and increased aqueous humor outflow.. PROVOCHOLINE is a Cholinergic Agonist that works by Parasympathomimetic agent that acts as a direct cholinergic agonist at muscarinic receptors, increasing exocrine gland secretion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OCUSERT PILO-40 and PROVOCHOLINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OCUSERT PILO-40 is: One OCUSERT Pilo-40 (2.5 mcg/hr pilocarpine) inserted into the conjunctival cul-de-sac every 7 days.. The standard adult dose of PROVOCHOLINE is: Subcutaneous: 2.5-5 mg; if no response, repeat with 5-10 mg; maximum single dose 10 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OCUSERT PILO-40 and PROVOCHOLINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OCUSERT PILO-40 is classified as Category C. Pilocarpine is a pregnancy category C drug. Animal studies have shown embryotoxic effects. In the first trimester, there is a potential risk of malformations. In the second and thi. PROVOCHOLINE is classified as Category C. Pregnancy Category C. Based on animal studies and limited human data, PROVOCHOLINE (methacholine) is not expected to increase the risk of major congenital malformations. However, b. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.